Clinically, these findings suggest that BTBD19 expression could serve as a predictive biomarker for response to immune checkpoint blockade, with high BTBD19 levels potentially indicating reduced sensitivity to PD-1/PD-L1 inhibitors-a critical consideration for personalized treatment strategies in CRC. Here, CD274 is linked to colorectal carcinoma.